Exenatide: pharmacokinetics, clinical use, and future directions

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial

(2016) Rury R. Holman et al.   AMERICAN HEART JOURNAL

Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes

(2016) Stephen Brunton et al.   CLINICAL THERAPEUTICS

Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial

(2016) Carol H. Wysham et al.   DIABETES CARE

Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study

(2016) Robert R. Henry et al.   Diabetes Technology & Therapeutics

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

(2016) Juan P Frías et al.   Lancet Diabetes & Endocrinology

Five-Year Efficacy and Safety Data of Exenatide Once Weekly

(2015) Carol H. Wysham et al.   MAYO CLINIC PROCEEDINGS

Observational Study of Kidney Function and Albuminuria in Patients With Type 2 Diabetes Treated With Exenatide BID Versus Insulin Glargine

(2014) Manjiri Pawaskar et al.   ANNALS OF PHARMACOTHERAPY

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

(2014) Hui Fan et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

Once-Weekly Exenatide as Adjunct Treatment of Type 1 Diabetes Mellitus in Patients Receiving Continuous Subcutaneous Insulin Infusion Therapy

(2014) Andrea N. Traina et al.   Canadian Journal of Diabetes

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

In This Issue ofDiabetes Care

(2014)   DIABETES CARE

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

(2014) Carol Wysham et al.   DIABETES CARE

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

(2014) Ning Shao et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus

(2014) Paul L. McCormack   DRUGS

Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes

(2014) Robert R. Henry et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

(2014) Michaela Diamant et al.   Lancet Diabetes & Endocrinology

Effects of Exenatide on Kidney Function, Adverse Events, and Clinical End Points of Kidney Disease in Type 2 Diabetes

(2013) Katherine R. Tuttle et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes☆☆This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

(2013) Robert R. Henry et al.   CLINICAL THERAPEUTICS

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges

(2013) Tara Ghazi et al.   DIABETES CARE

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes

(2013) Gayatri Sarkar et al.   DIABETES CARE

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)

(2013) J. Rosenstock et al.   DIABETES CARE

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes

(2013) Robert R. Henry et al.   DIABETES CARE

Do GLP-1-Based Therapies Increase Cancer Risk?

(2013) M. A. Nauck et al.   DIABETES CARE

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study

(2013) K.V.S. Hari Kumar et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Exenatide – pharmacokinetics, pharmacodynamics, safety and tolerability in patients >= 75 years of age with Type 2 diabetes

(2013) H. Linnebjerg et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus (对中国2型糖尿病患者单次和多次给予艾塞那肽周制剂的药代动力学、安全性和耐受性研究)

(2013) Yi Min Cui et al.   Journal of Diabetes

The Effect of Glucagon-Like Peptide-1 Receptor Agonist Therapy on Body Mass Index in Adolescents With Severe Obesity

(2013) Aaron S. Kelly et al.   JAMA Pediatrics

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

(2012) Aaron S Kelly et al.   Cardiovascular Diabetology

Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia

(2012) Jacob Lønborg et al.   Circulation-Cardiovascular Interventions

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks

(2012) M. Diamant et al.   DIABETES CARE

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks

(2012) R. M. Bergenstal et al.   DIABETES OBESITY & METABOLISM

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment

(2012) M. S. Fineman et al.   DIABETES OBESITY & METABOLISM

Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis

(2012) M. Pendergrass et al.   DIABETES OBESITY & METABOLISM

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

(2012) Daniel J. Cuthbertson et al.   PLoS One

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

(2011) J. Dushay et al.   DIABETES CARE

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

(2011) D. Russell-Jones et al.   DIABETES CARE

Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

(2011) Mary Beth DeYoung et al.   Diabetes Technology & Therapeutics

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

(2011) C. Wysham et al.   DIABETIC MEDICINE

Successful Treatment of Prediabetes in Clinical Practice: Targeting Insulin Resistance and β-Cell Dysfunction

(2011) John Armato et al.   Endocrine Practice

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

(2011) Jacob Lønborg et al.   EUROPEAN HEART JOURNAL

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

(2011) Thomas Blevins et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials

(2011) John B. Buse et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide as a Weight-Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study

(2011) Aaron S. Kelly et al.   Obesity

Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes

(2011) Vanita R. Aroda et al.   POSTGRADUATE MEDICINE

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

(2010) Mark Fineman et al.   CLINICAL PHARMACOKINETICS

Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes

(2010) J. Koska et al.   DIABETES CARE

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

(2010) J. Rosenstock et al.   DIABETES CARE

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

(2010) Lotte Bjerre Knudsen et al.   ENDOCRINOLOGY

Open label extension studies and patient selection biases

(2010) Karla Hemming et al.   JOURNAL OF EVALUATION IN CLINICAL PRACTICE

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

(2010) Michaela Diamant et al.   LANCET

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes

(2009) Kazuya IWAMOTO et al.   ENDOCRINE JOURNAL

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET